Plain-English translation of NCT07151885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new type of ultrasound technology called subharmonic imaging to see if it can better identify patients with liver cirrhosis who have developed dangerous enlarged veins in the esophagus and stomach. Researchers will combine this ultrasound technique with two other measurements — how stiff your liver is and your platelet count — to create a better way to detect these serious complications. The goal is to help doctors identify patients at highest risk before dangerous bleeding occurs.
Patients with cirrhosis often develop enlarged, fragile veins in the esophagus and stomach that can burst and cause life-threatening bleeding. Currently, doctors use an uncomfortable camera test (endoscopy) to find these veins. This study aims to develop a non-invasive ultrasound-based method that could more easily and accurately identify which patients are at highest risk, so doctors can treat them before bleeding happens.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will undergo a specialized ultrasound scan of your liver where doctors will inject a contrast dye (similar to a regular ultrasound) to measure the pressure differences in your liver's blood vessels. This scan will be combined with standard liver stiffness measurement (a type of ultrasound that checks how firm your liver is) and a routine blood test to check your platelet count. The entire process is non-invasive and painless, and researchers will use these three measurements together to evaluate whether they can accurately predict which patients are at highest risk for dangerous enlarged veins.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
The First Hospital of Jilin University
Enrollment target
~380 participants
Started
August 2025
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dezhi Zhang, doctorate
The First Hospital of Jilin University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.